| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036428 |
| Receipt No. | R000041499 |
| Scientific Title | A Preliminary Study of an Anti-Wrinkle Product for a 12-Week Application. |
| Date of disclosure of the study information | 2019/04/10 |
| Last modified on | 2019/10/08 (Ver. 3) |
| Basic information | ||
| Public title | A Preliminary Study of an Anti-Wrinkle Product for a 12-Week Application. | |
| Acronym | A Preliminary Study of an Anti-Wrinkle Product for a 12-Week Application. | |
| Scientific Title | A Preliminary Study of an Anti-Wrinkle Product for a 12-Week Application. | |
| Scientific Title:Acronym | A Preliminary Study of an Anti-Wrinkle Product for a 12-Week Application. | |
| Region |
|
|
| Condition | ||
| Condition | N/A (healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims to examine an effect of an anti-wrinkle product for a 12-week application and its safety. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | [1]Indexes for evaluating skin condition (doctor's questions and assessment of skin condition(1), photo evaluation(1), skin quality evaluation(1), wrinkle topography(2)).
(1)Screening, Week 0, Week 4, Week 8, Week 12. (2)Week 0, Week 4, Week 8, Week 12. |
| Key secondary outcomes | [1]Questionnaires about skin condition (Week 0, Week 4, Week 8, Week 12).
[2]Subject's diary (From the first day of ingestion of a test material to the last day of the test). |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Applying test products (applying test product A [right face] vs applying test product B [left face]). | |
| Interventions/Control_2 | Applying test products (applying test product B [right face] vs applying test product A [left face]). | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | [1]Japanese female aged 35-55 years.
[2]Individuals whose wrinkle grade is 3.0 -5.0*. [3]Individuals whose do not apply cosmetics and cuasi-drugs for anti-wrinkle. [4]Individuals who apply 1-3 products for skin care after washing. [5]Individuals who can stop drinking alcohol during the test period. [6]Individuals whose written informed consent has been obtained. *Task Force Committee for Evaluation of Anti-aging Function. Guideline for Evaluation of Anti-wrinkle Products. Journal of Japanese Cosmetic Science Society, 30(4): 316-332, 2006. |
|||
| Key exclusion criteria | [1]Individuals with chronic skin disease, such as atopic dermatitis.
[2]Individuals with strange skin conditions at measurement points. [3]Individuals who had been conducted an operation on the test spot. [4]Individuals who is a patient of hay fever and take a drug. [5]Individuals who were took a special facial treatment in the past 1 month. [6]Individuals who have a habit to ingest supplements claiming for brightening effect. [7]Individuals who cannot avoid daylight exposure during the test period. [8]Individuals who had ingested health-promoting foods, foods for specified health uses, health foods, or supplements being effective for the study. [9]Individuals who have a history of serious heart disease, kidney damage, and endocrine disease. [10]Individuals who conduct or have conducted hormone replacement therapy for menopausal disorder. [11]Individuals who take tabaco or alcohol regularly or whose eating habit is irregularity. [12]Subjects who are pregnant or breast-feeding. [13]Individuals judged inappropriate for the trial by the principal. |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical Corporation Kojinkai | ||||||
| Division name | Chief Director | ||||||
| Zip code | 064-0807 | ||||||
| Address | 2-1-4 Minami Nanajo Nishi, Chuo-ku, Sapporo 0640807, JAPAN | ||||||
| TEL | +81-11-221-8807 | ||||||
| sapporo@kojinkai.org | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TES Holdings Co., Ltd. | ||||||
| Division name | Administrative Department of Clinical Trials | ||||||
| Zip code | 110-0015 | ||||||
| Address | 6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN | ||||||
| TEL | +81-3-6801-8480 | ||||||
| Homepage URL | |||||||
| r.shimizu@tes-h.co.jp | |||||||
| Sponsor | |
| Institute | Derma Labo, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | LG Household & Health Care Ltd |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Republic of Korea |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ueno-Asagao Clinic Ethical Review Committee |
| Address | Kairaku Building 6F, 2-7-5, Higashiueno, Taito-ku, Tokyo, 110-0015 JAPAN |
| Tel | +81-3-6240-1162 |
| i.takahashi@tes-h.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 20 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041499 |